Abiopharma

New data for Roches Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)

Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension

Aduro Clean Technologies participera à des conférences en septembre et lancera une campagne de relations publiques

Aduro Clean Technologies nimmt an Konferenzen im September teil und startet PR-Kampagne

Micron pledges AI education investment to accelerate opportunities for Americas youth

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

New Form SCHEDULE 13G - FEMASYS INC Filed: 2025-09-04 AccNo: 0001213900-25-084691 Size: 17 KB

Zalevsky Jonathan 🔴 sold 485 shares of NEKTAR THERAPEUTICS (NKTR) at $30.10 Transaction Date: Sep 02, 2025 | Filing ID: 113130

ROBIN HOWARD W 🔴 sold 1.5K shares of NEKTAR THERAPEUTICS (NKTR) at $30.16 Transaction Date: Sep 02, 2025 | Filing ID: 113129

Future Mineral Changes Name, Consolidates Shares, and Closes Shares for Debt Settlements

Swayze Eric 🔴 sold 11.1K shares of IONIS PHARMACEUTICALS INC (IONS) at $53.68 Transaction Date: Sep 02, 2025 | Filing ID: 000224

Director WENDER JOSEPH H 🔴 sold 28.0K shares of IONIS PHARMACEUTICALS INC (IONS) at $60.14 ($1.6M) Transaction Date: Sep 02, 2025 | Filing ID: 000223

Director PARSHALL B LYNNE 🔴 sold 20.0K shares of IONIS PHARMACEUTICALS INC (IONS) at $51.49 ($1.0M) Transaction Date: Sep 02, 2025 | Filing ID: 000222

Director Monia Brett P 🟡 adjusted position in 203.8K shares (4 derivative) of IONIS PHARMACEUTICALS INC (IONS) at $61.06 ($30.4M) Transaction Date: Sep 03, 2025 | Filing ID: 000221